Results 221 to 230 of about 9,592 (241)

Asunaprevir/daclatasvir

Reactions Weekly, 2015
openaire   +2 more sources

Daclatasvir

Reactions Weekly, 2017
openaire   +1 more source

Asunaprevir/daclatasvir

Reactions Weekly, 2020
openaire   +1 more source

The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19

Journal of Antimicrobial Chemotherapy, 2020
Saeid Bitaraf, Bryony Simmons, Andrew M Hill   +2 more
exaly  

Evaluation of the effect of sofosbuvir and daclatasvir in hospitalized COVID-19 patients: a randomized double-blind clinical trial (DISCOVER)

Journal of Antimicrobial Chemotherapy, 2021
Sara Mobarak, Ahmad Hormati, Masood Ziaee   +2 more
exaly  

Asunaprevir/daclatasvir

Reactions Weekly, 2019
openaire   +2 more sources

All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study

Lancet, The, 2014
Michael Manns, Stanislas Pol, Patrick Marcellin   +2 more
exaly  

Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: Potent antiviral activity but no clinical benefit if treatment is given late

Digestive and Liver Disease, 2014
Marzia Montalbano, Raffaella Lionetti, Peter Ferenci   +2 more
exaly  

Development and validation of a simple and robust HPLC method with UV detection for quantification of the hepatitis C virus inhibitor daclatasvir in human plasma

Journal of Pharmaceutical and Biomedical Analysis, 2017
Giulio Nannetti, Lorenzo Messa, Monica Basso   +2 more
exaly  

Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme

Liver International, 2017
Christophe Hézode, Fabien Zoulim, Christine Silvain   +2 more
exaly